A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

NCT00135395 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Atazanavir+ritonavir
DRUG: Lopinavir+ritonavir

Sponsor

Bristol-Myers Squibb